Genzyme - Wikipedia
Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 …
Genzyme’s Contributions to Genetics and Genetic Disease
Nov 19, 2025 · Genzyme was a pioneering biotechnology company that fundamentally reshaped the medical landscape for patients suffering from rare genetic disorders. The company’s focus on …
Genzyme: Pioneering Rare Disease Treatments - Biology Insights
Aug 2, 2025 · Genzyme was founded in 1981, aiming to apply advanced biotechnology to develop treatments for diseases. Its founders recognized a need for innovative approaches to conditions that …
Sanofi issued warning letter for Genzyme cGMP failures
Jan 21, 2025 · In a warning letter dated 15 January, the FDA wrote that it had serious concerns about manufacturing issues with Sanofi’s former subsidiary Genzyme Corporation’s manufacturing facility …
Eleven years after buying Genzyme, Sanofi officially ditches ... - STAT
Feb 3, 2022 · Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a ...
Genzyme Corporation -- Company History
The TSI acquisition was made by Genzyme Transgenics Corp., created by Genzyme in 1993 to promote and develop technology combining recombinant microbiology and experimental embryology to …
Genzyme Corporation Company Information - Drugs.com
Aug 1, 2014 · Genzyme Corporation manufactures, markets and/or distributes more than 10 drugs in the United States. Medications listed here may also be marketed under different names in different …
Sanofi Genzyme Company Profile - Office Locations, Competitors
Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. It is engaged in the …
Genzyme's Growth Story - Guidechem Chemical Network
Nov 18, 2024 · Genzyme's growth story showcases a biotech company that thrived through diversification and innovative financing strategies. Despite challenges, including its reliance on rare …
Eleven years after buying Genzyme, Sanofi officially ditches subsidiary ...
Feb 3, 2022 · Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a …